TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: The concentration of interleukin 4(IL-4), interleukin 5(IL-5), interleukin 13(IL-13)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: FDG uptake TBR as a marker of arterial plaque inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of pain after caesarean section
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of inadequate analgesia
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of Deep Learning Model in Classifying Breast Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Complete response (CR) rate at day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alanine transaminase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diagnostic performance of immunological tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of molecular tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in NFL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Tau protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in GFAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in UCHL1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to first clinical diagnosis of Catheter-related Bloodstream Infections (CRBSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sedentary behavior time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in antibody profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cellular Immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in severity of symptoms of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in level of functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Level of 25(OH)D in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum level of inflammatory mediators of RA (IL6, IL17, CRP, TNF-alpha)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence of active bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PUSH score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of women with placenta accreta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Development of diarrheal adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Recurrence Free Rate
Endpoint domain: Mortality/survival
Primary endpoint: Rate of concordance between AI-estimated results and actual culture results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of i-gel placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Engaged Living Scale
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Acceptability of participation in the class
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of respiratory instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Antibiotic resistance profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of Serious Bacterial Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Average total IgG concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quadriceps and hamstring muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of patients with chronic hepatic and/or digestive abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of patients with an identified enteric virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Symptomatic improvement in Boston Carpal Tunnel Syndrome Questionnaire (BCTSQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Symptomatic improvement in Michigan Hand Outcomes Questionnaire (MHQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of clinically relevant microorganisms identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Service quality via Mystery Shopper Assessments composite
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Back Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Plasmodium falciparum parasite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Success of weaning from mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in parental psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Location of brain functional activation areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Peak T-value size of the activation region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visual Analog Scale (VAS) of oral lichen planus lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to regional nodal recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Impact of multiple doses of RCT1100 on MCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Doppler ultrasound results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urodynamic assessment results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal IFN-λ levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Duruöz Hand Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90-day Modified Rankin Scale ordinal shift
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: detection rate of stage II+ cancers per 1000 screens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: interval cancer rate per 1000 screens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Satisfaction with study procedures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ELISA assessment of IgG anti Spike (UI/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of eligible patients completing initial MRI
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of eligible patients completing cerebrospinal fluid (CSF) evaluation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to complete drainage after thoracentesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Short physical performance battery scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic Gait Index scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dizziness handicap inventory scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Generalized Anxiety Disorder-7 scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Mean Diurnal Intraocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbial growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of Long Term Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the concentration-time curve (AUC0-8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to renal remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Alzheimer's Disease Assessment Scale cognitive subscale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quadriceps maximal isometric contraction force differential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Severity of dialysis-associated symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uric acid levels as a predictor of lupus nephritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Behavioral assessment using IOWA Conners Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Behavioral assessment using Disruptive Behavior Disorders (DBD) Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Behavioral assessment using Impairment Rating Scale - Parent/Teacher Version (IRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of dead participants at the end of hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Incretin effect's restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Vascular closure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rates of grade III/IV neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rates of febrile neutropenia (FN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of tissue samples obtained successfully over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of aspirate samples obtained successfully overall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of tissue samples successfully producing microbiome data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local perfusion parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Platelet response on day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Panic disorder symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from marrow blast in percentage at Week 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Range of motion with knee extended
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion with knee flexed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose or clinically recommended dose
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Events, Serious Adverse Events, Adverse Events of Particular Concern
Endpoint domain: Adverse events/effects
Primary endpoint: GIT disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intrahepatic objective response rate (hORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Allele frequency of HLA-alleles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of sports injuries and illnesses at 6 months
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of sports injuries and illnesses at 12 months
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of sports injuries and illnesses at 4 years
Endpoint domain: Adverse events/effects
Primary endpoint: Core Endurance Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Lens nuclear opalescence (NO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pentacam mean nuclear density (PND)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean nucleus density (MND) of the lens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal allograft tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Chimeric transition syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Successful Accessory placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of feeding tube complications
Endpoint domain: Adverse events/effects
Primary endpoint: Operational efficiency
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Skeletal muscle health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sensitivity of apnoea detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of apnoea detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of uropathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of patients negative for repeat testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Validity and reliability of the assessment log
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms Assessment Questionnaire in Dry Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: National Eye Institute grading scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of tears' production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tears Break Up Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with coagulation disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Minimum toe clearance during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior stability margins during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior reactive stepping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee extensor fatigability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of infants with B cell levels below LLN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood lymphocyte proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of participants who withdraw from course
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of participants who attend at least 4 of 6 intervention sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of participants who rate the course as acceptable or completely acceptable
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of intervention topics covered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: changes in lymphocyte populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: changes in natural killer (NK) cell activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: changes in complete blood count (CBC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of women developing UTI
Endpoint domain: Adverse events/effects
Primary endpoint: Unilateral Upper Limb Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of intralesional triamcinolone injection
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of venous thromboembolism (VTE) recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of all cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: TB-Related Unfavorable Outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Investigator-Assessed Overall Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of bronchiolitis obliterans syndrome (BOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Masticatory Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective masticatory performance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the concentration-time curve from 0 to 24 hours postdose (AUC0-24hr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with overall mortality
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bodyweight at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful positioning of ventricular lead
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: WIC enrollment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Efficacy - Investigator global assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: RosaQoL change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Demodex count change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with orthopedic implant-associated infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Successful patient use of a 3D printed Custom foot orthotic
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reach HIV counseling
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Effectiveness HIV counseling
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reach Linked to HIV care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Effectiveness Linked to HIV care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reach Screening and linkage to PrEP
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Effectiveness Screening and linkage to PrEP
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Histopathological changes in myocardial tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of newly diagnosed head and neck cancer patients recruited and retained on study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Treatment Emergent Adverse Events (TEAEs) and Treatment-related AEs by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity and specificity of BCDx
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value (NPV) of BCDx
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value (PPV) of BCDx
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Taste Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Liking of the samples
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Appetite - Composite Appetite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Current age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suicide composite
Endpoint domain: Mortality/survival
Primary endpoint: Referral Rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: MOUD Prescription
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Beliefs Questionnaire (PBQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Weeks in Response Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-tumor efficacy evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes